Polymyxin B Regulatory History: From Discovery to Modern Approval

The Discovery Era: 1940s–1950s

Polymyxin B's story begins in the soil. In the 1940s, researchers isolating antibacterial compounds from Bacillus polymyxa identified a family of cyclic peptide antibiotics with extraordinary potency against gram-negative bacteria. Polymyxin B emerged as one of the most active members of this class. Early laboratory work demonstrated it could kill bacteria that were otherwise untreatable—a remarkable finding in an era when antibiotics were still new and precious.

However, initial clinical enthusiasm was tempered by a harsh reality: Polymyxin B was highly nephrotoxic (poisonous to the kidneys) and neurotoxic. Animal studies and early human trials revealed that the doses needed to treat serious infections often caused severe kidney damage and neurological complications. This toxicity profile pushed Polymyxin B to the margins of clinical practice, where it was reserved only for life-threatening infections with no alternatives.

The Dormant Period: 1960s–1980s

As a new generation of safer, broader-spectrum antibiotics flooded the market—penicillins, cephalosporins, fluoroquinolones—Polymyxin B faded from routine use. The drug was never truly abandoned in all regions, but it became a footnote in most developed-world formularies. Clinical research slowed to a trickle. Paradoxically, this period of disuse would prove protective: while other antibiotics faced mounting resistance pressure, Polymyxin B remained relatively uncommon, and resistance to it evolved slowly.

During this era, Polymyxin B retained a foothold in topical formulations (eye drops, ointments) and retained minor use in some oral and parenteral contexts, but systemic use declined sharply.

The Resistance Crisis: 1990s–2000s

By the 1990s, gram-negative bacteria—particularly Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae (CRE)—were acquiring resistance to nearly every modern antibiotic. Hospitals faced the spectre of truly untreatable infections. In this crisis, attention turned back to old drugs: Polymyxin B and its sister compound Colistin (Polymyxin E).

Clinicians and researchers began systematically re-examining Polymyxin B's safety profile. New studies questioned whether toxicity had been overstated—or whether modern understanding of renal function and drug monitoring could mitigate it. A landmark 2005 review synthesized decades of data, concluding that Polymyxin B, when dosed carefully and monitored rigorously, was tolerable in desperate situations. Clinical case series and small trials demonstrated efficacy in multiresistant gram-negative infections.

This shift in perception marked the beginning of Polymyxin B's regulatory and clinical resurrection.

FDA Regulatory Modernisation: 2000s–2010s

Polymyxin B's regulatory status is itself revealing. The drug was first approved by the FDA in 1949, during the pre-modern era of antibiotic regulation. It retained a legacy FDA approval—a grandfathered status—meaning it had never been formally required to submit to modern New Drug Application (NDA) trials and review standards.

In 2007, the FDA acknowledged the clinical need for Polymyxin B in the context of resistant gram-negative infections. However, rather than demand a full NDA, the agency worked pragmatically with existing manufacturers to improve labeling, standardize manufacturing, and sponsor re-evaluation of safety and efficacy in the modern clinical context. The FDA's Guidance for Industry on Polymyxins reflected recognition that this older compound could play a vital role if used appropriately.

Clinical trial activity began to increase. By 2010, researchers had published 40+ clinical studies; by 2020, the count exceeded 60, with 66 trials now registered on ClinicalTrials.gov. These trials have focused on:

• Safety and pharmacokinetics in modern renal monitoring
• Efficacy in specific resistant pathogens
• Combination therapy strategies
• Dosing optimization
• Comparison with Colistin

Key Regulatory Milestones (Modern Era)

2009–2012: Multiple professional societies—the Infectious Diseases Society of America (IDSA) and others—formally included Polymyxin B in treatment guidelines for multidrug-resistant (MDR) gram-negative infections. This was a signal that the drug's regulatory and clinical status had fundamentally shifted from "last-resort forgotten drug" to "essential reserve antibiotic."

2014: The FDA issued draft guidance supporting expanded clinical development and improved data generation for older antibiotics like Polymyxin B. The agency recognized that legacy approvals, while technically valid, could be strengthened through additional well-designed trials.

2015–Present: Continued clinical trial activity. Major studies have examined Polymyxin B's efficacy and safety in ICU populations, nosocomial infections, and combination therapy. The European Medicines Agency (EMA) has not authorized Polymyxin B, though it is available via named-patient programs in some EU countries. Health Canada approved Polymyxin B, aligning with FDA and broader North American practice.

Regulatory Status Today

United States: Polymyxin B is FDA-approved for parenteral (intravenous/intramuscular) use in bacterial infections caused by susceptible gram-negative organisms. It remains available in both powder-for-injection formulations and, in some regions, as a veterinary and topical product.

Canada: Health Canada maintains approval for Polymyxin B, reflecting its recognized therapeutic role.

European Union: The EMA has not issued a centralized marketing authorization for Polymyxin B, though it is used in some member states under special arrangements. This reflects both lower disease burden from resistant gram-negatives in some regions and a preference for Colistin in others.

The Clinical Trial Landscape

With 66 clinical trials now registered, Polymyxin B has transitioned from a drug with minimal research infrastructure to one with genuine clinical momentum. Recent trials have addressed:

• Pharmacokinetics in special populations: renal impairment, obesity, critical illness
• Combination strategies: Polymyxin B + other agents (beta-lactams, aminoglycosides, fluoroquinolones) for synergy
• Comparative effectiveness: Polymyxin B vs. Colistin
• Safety monitoring: Studies refining understanding of nephrotoxicity risk factors

Related Compounds and the Broader Polymyxin Context

Polymyxin B is part of a larger antibiotic class. Colistin (Polymyxin E) is the most closely related compound; it has similar spectrum and mechanism but is more widely used globally and has been the subject of additional regulatory attention. Gentamicin, another aminoglycoside used in combination therapy, and Meropenem, a carbapenem, are often paired with Polymyxin B in synergistic regimens for the most resistant pathogens.

Understanding antimicrobial resistance is essential to understanding why Polymyxin B's regulatory resurgence matters: as resistance to most modern antibiotics climbs, older drugs like Polymyxin B become clinically invaluable. Conversely, the concept of pharmacokinetics—how the body absorbs, distributes, metabolizes, and excretes a drug—has been central to modern Polymyxin B research, enabling safer dosing strategies than were possible in earlier decades.

Current Status and Future Outlook

Polymyxin B today occupies a unique regulatory and clinical niche. It is no longer a forgotten relic, but it is also not a first-line agent. Instead, it has become what clinicians call a "reserve antibiotic"—powerful, proven, but reserved for situations where nothing else works.

Regulatory agencies, recognizing the global threat of antimicrobial resistance, have shifted their stance. Rather than retire old drugs, they are actively supporting research that can improve their safety and efficacy profiles. Polymyxin B exemplifies this new pragmatism: a 75-year-old antibiotic, FDA-approved since 1949, has experienced a genuine clinical and regulatory renaissance in the 21st century.